Bohorquez, Humberto E.; Cohen, Ari J.; Girgrah, Nigel; Bruce, David S.; Carmody, Ian C.; Joshi, Shoba; Reichman, Trevor W.; Therapondos, George; Mason, Andrew L.; Loss, George E.
The use of livers from hepatitis B surface antigen-negative (HBsAg-)/hepatitis B core antibody-positive (HBcAb+) donors in liver transplantation (LT) for HBsAg-/HBcAb- recipients is still controversial because of a lack of standard antiviral prophylaxis and long-term follow-up. We present our 13-year experience with the use of HBcAb+ donor livers in HBcAb- recipients. Patients received prophylaxis with hepatitis B immunoglobulin at the time of LT and then lamivudine daily. De novo hepatitis B virus (HBV) was defined as positive HBV DNA detection. Between January 1999 and December 2010, 1013 adult LT procedures were performed at our center. Sixty-four HBsAg-/HBcAb- patients (6.3%) received an HBsAg-/HBcAb+ liver. All donor sera were negative for HBcAb immunoglobulin M and HBV DNA. The mean follow-up was 48.8 +/- 40.1 months (range=1.2-148.8). Both the patient survival rates and the graft survival rates were 92.2% and 69.2% at 1 and 5 years, respectively. No graft losses or deaths were related to de novo HBV. Nine of the 64 patients (14.1%) developed de novo HBV. The mean time from LT to de novo HBV was 21.4 +/- 26.1 months (range=10.8-92.8 months). De novo HBV was successfully treated with adefovir or tenofovir. In conclusion, HBcAb+ allografts can be safely used in HBcAb- recipients without increased mortality or graft loss. Lifelong prophylaxis, continuous surveillance, and compliance are imperative for success. Should a de novo infection occur, our experience suggests that a variety of treatments can be employed to salvage the graft and obtain serum HBV DNA clearance. Liver Transpl 19:611-618, 2013. (c) 2013 AASLD.